Evaluation of Investigational (Frequent Replacement) FRP Lens for Daily Wear

September 24, 2020 updated by: CooperVision, Inc.

Evaluation of the CooperVision, Inc. Sapphire and Pearl Silicone Hydrogel Daily Wear Contact Lenses When Used for Frequent Replacement for Up to One (1) Month of Daily Wear.

The purpose of the study is to compare the investigational contact lens to a marketed contact lens.

The study results were not used for design validation of investigational contact lens,

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The objective of this evaluation is to provide evidence supporting the claim that the performance of the Test Lens is substantially equivalent to that of the Control Lens when used in a one month (up to 30 days) recommended replacement, daily wear modality.

The study results were not used for design validation of investigational contact lens,

Study Type

Interventional

Enrollment (Actual)

89

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • San Diego, California, United States, 92123
        • Eric M White OD, Inc.
      • Torrance, California, United States, 90503
        • Office of Mark E Nakano, O.D.
    • North Carolina
      • Denver, North Carolina, United States, 28037
        • Advanced Family Eye Care
    • Ohio
      • Athens, Ohio, United States, 45701
        • Quinn Foster & Associates
    • Tennessee
      • Brentwood, Tennessee, United States, 37027
        • Primary Eyecare Group, P.C.
    • Texas
      • Amarillo, Texas, United States, 79119
        • Premier Vision Services, LLC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Prior to being considered eligible to participate in this study, each subject MUST:

    1. Be at least 18 years of age as of the date of evaluation for the study.
    2. Have:

      1. Read the Informed Consent
      2. been given an explanation of the Informed Consent
      3. indicated understanding of the Informed Consent
      4. signed the Informed Consent document.
    3. Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
    4. Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses at least 5 days per week for at least 8 hours per day for at least one month prior to participation in the study.
    5. Possess or obtain prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses.
    6. Be in good general health, based on his/her knowledge.
    7. Require spectacle lens powers between -0.50 and -8.00 diopters sphere with no more than 1.50 diopter of refractive astigmatism and be willing to wear contact lenses in both eyes.
    8. Have manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 in each eye.
    9. To be eligible for lens dispensing, the subject must achieve 20/30 VA or better in each eye with the study lens and the investigator must judge the fit as acceptable or optimal.

Exclusion Criteria:

  • Subjects may not be enrolled in this study if any of the following apply: The subject is currently or has:

    1. Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes for the duration of the study. NOTE: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis.
    2. Poor personal hygiene.
    3. Any active participation in another clinical trial during this trial or within 30 days prior to this study.
    4. To the best of the subject's knowledge, she is currently pregnant, is lactating or is planning a pregnancy within the next 3 months.
    5. A member, relative or household member of the investigator or of the investigational office staff.
    6. Has a known sensitivity to the ingredients used in the MPS approved for use in the study and is unable or unwilling to use the alternate care system.
    7. Previous refractive surgery; or current or previous orthokeratology treatment.
    8. Is aphakic or psuedophakic.
    9. Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, scleroderma, keratoconus or uncontrolled diabetes.
    10. The need for topical ocular medications or any systemic medication which might interfere with contact lens wear or require the lenses to be removed during the day.
    11. The presence of clinically significant (grade 2, 3 or 4) anterior segment abnormalities; or the presence of any inflammations such as iritis; or any infection of the eye, lids, or associated structures.
    12. A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, iritis, bacterial or fungal infections.
    13. A history of papillary conjunctivitis that has interfered with contact lens wear.
    14. Slit lamp findings that would contraindicate contact lens wear, including but not limited to:

      • Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining > Grade 2
      • Pterygium
      • Corneal scars within the visual axis
      • Neovascularization or ghost vessels > 1.0 mm in from the limbus
      • Giant papillary conjunctivitis (GPC) of > Grade 2
      • Anterior uveitis or iritis
      • Seborrheic eczema, seborrheic conjunctivitis or blepharitis

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Sapphire
Subjects randomized to the experimental contact lens over the study duration
silicone hydrogel contact lens
Active Comparator: Pearl
Subjects randomized to the active comparator contact lens over the study duration
silicone hydrogel contact lens

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Slit Lamp Findings for Epithelial Edema
Time Frame: Baseline (After lens dispensing)
Slit Lamp Findings for Epithelial Edema on a grade of 0-4 (0 NONE: No microcysts; normal transparency, 1 TRACE: 1 to 20 microcysts; barely discernible local epithelial haziness, 2 MILD: 21 to 50 microcysts; faint but definite localized or generalized haziness, 3 MODERATE: 51 to 100 microcysts; significant localized or generalized haziness, 4 SEVERE: >100 microcysts; definite widespread epithelial cloudiness giving a dull glass appearance to the cornea, or numerous coalescing bullae)
Baseline (After lens dispensing)
Slit Lamp Findings for Epithelial Edema
Time Frame: 1 Month
Slit Lamp Findings for Epithelial Edema on a grade of 0-4 (0 NONE: No microcysts; normal transparency, 1 TRACE: 1 to 20 microcysts; barely discernible local epithelial haziness, 2 MILD: 21 to 50 microcysts; faint but definite localized or generalized haziness, 3 MODERATE: 51 to 100 microcysts; significant localized or generalized haziness, 4 SEVERE: >100 microcysts; definite widespread epithelial cloudiness giving a dull glass appearance to the cornea, or numerous coalescing bullae)
1 Month
Slit Lamp Findings for Stromal Edema
Time Frame: Baseline (After lens dispensing)
Slit Lamp Findings for Stromal Edema on a grade of 0-4 (0 NONE: No edema, 1 TRACE: Just detectable clouding, 2 MILD: Faint corneal striae (2 or fewer), 3 MODERATE: Pronounced corneal striae (3), 4 SEVERE: Folds in Descemet's membrane and >4 pronounced striae)
Baseline (After lens dispensing)
Slit Lamp Findings for Stromal Edema
Time Frame: 1 month
Slit Lamp Findings for Stromal Edema on a grade of 0-4 (0 NONE: No edema, 1 TRACE: Just detectable clouding, 2 MILD: Faint corneal striae (2 or fewer), 3 MODERATE: Pronounced corneal striae (3), 4 SEVERE: Folds in Descemet's membrane and >4 pronounced striae)
1 month
Slit Lamp Findings for Corneal Infiltrates
Time Frame: Baseline (After lens dispensing)
Slit Lamp Findings for Corneal Infiltrates - Present, Absent
Baseline (After lens dispensing)
Slit Lamp Findings for Corneal Infiltrates
Time Frame: 1 Month
Slit Lamp Findings for Corneal Infiltrates - Present, Absent
1 Month
Slit Lamp Findings for Corneal Vascularization
Time Frame: Baseline (After lens dispensing)
Slit Lamp Findings for Corneal Vascularization on a grade 0-4 (0 NONE: No vessel penetration, 1 TRACE: <1.00 mm vessel penetration, 2 MILD: >1.00 mm to <1.50 mm vessel penetration, 3 MODERATE: >1.50 mm to <2.00 mm vessel penetration, 4 SEVERE: Vessel penetration >2.00 mm)
Baseline (After lens dispensing)
Slit Lamp Findings for Corneal Vascularization
Time Frame: 1 month
Slit Lamp Findings for Corneal Vascularization on a grade 0-4 (0 NONE: No vessel penetration, 1 TRACE: <1.00 mm vessel penetration, 2 MILD: >1.00 mm to <1.50 mm vessel penetration, 3 MODERATE: >1.50 mm to <2.00 mm vessel penetration, 4 SEVERE: Vessel penetration >2.00 mm)
1 month
Slit Lamp Findings for Limbal Hyperemia
Time Frame: Baseline (After lens dispensing)
Slit Lamp Findings for Limbal Hyperemia on a grade 0-4 (0 NONE: No hyperemia present, 1 TRACE: Slight regional hyperemia, 2 MILD: Diffuse hyperemia, 3 MODERATE: Marked regional or diffuse hyperemia, 4 SEVERE: Diffuse episcleral or scleral hyperemia)
Baseline (After lens dispensing)
Slit Lamp Findings for Limbal Hyperemia
Time Frame: 1 month
Slit Lamp Findings for Limbal Hyperemia on a grade 0-4 (0 NONE: No hyperemia present, 1 TRACE: Slight regional hyperemia, 2 MILD: Diffuse hyperemia, 3 MODERATE: Marked regional or diffuse hyperemia, 4 SEVERE: Diffuse episcleral or scleral hyperemia)
1 month
Slit Lamp Findings for Bulbar Hyperemia
Time Frame: Baseline (After lens dispensing)
Slit Lamp Findings for Bulbar Hyperemia on a grade 0-4 (0 NONE: No hyperemia present, 1 TRACE: Slight regional hyperemia, 2 MILD: Diffuse hyperemia, 3 MODERATE: Marked regional or diffuse hyperemia, 4 SEVERE: Diffuse episcleral or scleral hyperemia)
Baseline (After lens dispensing)
Slit Lamp Findings for Bulbar Hyperemia
Time Frame: 1 month
Slit Lamp Findings for Bulbar Hyperemia on a grade 0-4 (0 NONE: No hyperemia present, 1 TRACE: Slight regional hyperemia, 2 MILD: Diffuse hyperemia, 3 MODERATE: Marked regional or diffuse hyperemia, 4 SEVERE: Diffuse episcleral or scleral hyperemia)
1 month
Slit Lamp Findings for Palpebral Conjunctiva
Time Frame: Baseline (After lens dispensing)
Slit Lamp Findings for Palpebral Conjunctiva - Present, Absent
Baseline (After lens dispensing)
Slit Lamp Findings for Palpebral Conjunctiva
Time Frame: 1 month
Slit Lamp Findings for Palpebral Conjunctiva - Present, Absent
1 month
Slit Lamp Findings for Other Findings
Time Frame: Baseline (After lens dispensing)
Slit Lamp Findings for Other findings (conjunctival infection, corneal ulcers, iritis, lens adhesions and recurrent erosion) on a grade 0-4 (0 NONE, 1 TRACE, 2 MILD, 3 MODERATE, 4 SEVERE)
Baseline (After lens dispensing)
Slit Lamp Findings for Other Findings
Time Frame: 1 month
Slit Lamp Findings for Other findings (conjunctival infection, corneal ulcers, iritis, lens adhesions and recurrent erosion) on a grade 0-4 (0 NONE, 1 TRACE, 2 MILD, 3 MODERATE, 4 SEVERE)
1 month

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Steven L Saltzman, MD, FACOG, Sterling IRB

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2015

Primary Completion (Actual)

June 1, 2015

Study Completion (Actual)

December 1, 2015

Study Registration Dates

First Submitted

February 2, 2015

First Submitted That Met QC Criteria

February 9, 2015

First Posted (Estimate)

February 13, 2015

Study Record Updates

Last Update Posted (Actual)

October 14, 2020

Last Update Submitted That Met QC Criteria

September 24, 2020

Last Verified

December 1, 2015

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FC131202

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ametropia

Clinical Trials on Sapphire

Subscribe